| Company Name: |
BePharm Ltd |
| Tel: |
400-685-9117 |
| Email: |
market@bepharm.com |
FPL 62064 manufacturers
- FPL 62064
-
- $31.00
-
2026-09-13
- CAS:103141-09-9
- Purity: 99.64%
- Supply Ability: 10g
|
| | FPL 62064 Basic information |
| Product Name: | FPL 62064 | | Synonyms: | 1H-Pyrazol-3-amine,N-(4-methoxyphenyl)-1-phenyl-;FPL 62064;N-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine;Cyclooxygenase,FPL 62064,LOX,5-lipoxygenase,FPL62064,inhibit,FPL-62064,Prostaglandin,5-LOX,COX,Inhibitor,synthetase,Lipoxygenase,anti-inflammatory,COX-2;FPL 62064, 10 mM in DMSO | | CAS: | 103141-09-9 | | MF: | C16H15N3O | | MW: | 265.31 | | EINECS: | | | Product Categories: | | | Mol File: | 103141-09-9.mol |  |
| | FPL 62064 Chemical Properties |
| Boiling point | 442.6±25.0 °C(Predicted) | | density | 1.15±0.1 g/cm3(Predicted) | | storage temp. | Keep in dark place,Sealed in dry,Room Temperature | | solubility | DMSO: 250 mg/mL (942.29 mM) | | pka | 2.42±0.50(Predicted) | | form | Solid | | color | Light yellow to yellow | | Cosmetics Ingredients Functions | ANTI-SEBUM |
| | FPL 62064 Usage And Synthesis |
| Uses | FPL 62064 is a potent 5-lipoxygenase (5-LOX) and COX dual inhibitor, with IC50 values of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and prostaglandin synthetase (cyclooxygenase), respectively. FPL 62064 has potent anti-inflammatory activity[1][2]. | | in vivo | FPL 62064 (5-20 mg/kg; intraperitoneal injection; female LACA mice) treatment inhibits peritoneal inflammation induced by immune-complex[1]. | Animal Model: | Female LACA mice (20-30 g) injected with immune complex[1]. | | Dosage: | 5 mg/kg, 10 mg/kg, 20 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Produced a dose-related inhibition of dye extravasation, leukotriene C4 (LTC4) and prostaglandin E2 (PGE2) formation. |
| | References | [1] Blackham A, et al. FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42. DOI:10.1007/BF01966309
[2] Shabaan MA, et al. Synthesis and biological evaluation of pyrazolone analogues as potential anti-inflammatory agents targeting cyclooxygenases and 5-lipoxygenase. Arch Pharm (Weinheim). 2020 Feb 7:e1900308. DOI:10.1002/ardp.201900308 |
| | FPL 62064 Preparation Products And Raw materials |
|